Biorestorative Therapies Inc. (BRTX)
What Makes Biorestorative Therapies (BRTX) a New Buy Stock
Biorestorative Therapies (BRTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Misses Revenue Estimates
Biorestorative Therapies, Inc. (BRTX) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.56 per share a year ago.
Here's Why Biorestorative Therapies (BRTX) Looks Ripe for Bottom Fishing
Biorestorative Therapies (BRTX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Biorestorative Therapies, Inc. (BRTX) Reports Q4 Loss, Lags Revenue Estimates
Biorestorative Therapies, Inc. (BRTX) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to a loss of $0.2 per share a year ago.
Biorestorative Therapies, Inc. (BRTX) Reports Q3 Loss, Lags Revenue Estimates
Biorestorative Therapies, Inc. (BRTX) came out with a quarterly loss of $0.38 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.13 per share a year ago.
BioRestorative Therapies, Inc. (BRTX) Q3 2025 Earnings Call Transcript
BioRestorative Therapies, Inc. ( BRTX ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Stephen Kilmer - Investor Relations Officer Lance Alstodt - Chairman of the Board, President & CEO Robert Kristal - Chief Financial Officer Francisco Silva - VP of Research & Development, Secretary and Director Conference Call Participants Michael Okunewitch - Maxim Group LLC, Research Division Jonathan Aschoff - ROTH Capital Partners, LLC, Research Division Presentation Operator Greetings. Welcome to the BioRestorative Therapies Third Quarter 2025 Results and Business Update Conference Call.
BioRestorative Therapies, Inc. (BRTX) Q2 2025 Earnings Call Transcript
BioRestorative Therapies, Inc. (NASDAQ:BRTX ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Francisco J. Silva - VP of Research & Development, Secretary and Director Lance Alstodt - Chairman of the Board, President & CEO Robert Eugene Kristal - Chief Financial Officer Stephen Kilmer - Investor Relations Officer Conference Call Participants Jonathan Matthew Aschoff - ROTH Capital Partners, LLC, Research Division Michael Okunewitch - Maxim Group LLC, Research Division Operator Greetings.
Biorestorative Therapies, Inc. (BRTX) Reports Q2 Loss, Beats Revenue Estimates
Biorestorative Therapies, Inc. (BRTX) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.5 per share a year ago.
BioRestorative Therapies, Inc. (BRTX) Q1 2025 Earnings Call Transcript
BioRestorative Therapies, Inc. (NASDAQ:BRTX ) Q1 2025 Earnings Call May 14, 2025 4:30 PM ET Company Participants Stephen Kilmer - Investor Relations Lance Alstodt - Chairman and Chief Executive Officer Francisco Silva - Vice President, Research and Development Robert Kristal - Chief Financial Officer Conference Call Participants Jonathan Aschoff - ROTH Jason McCarthy - Maxim Group Operator Good afternoon, everyone and welcome to the BioRestorative Therapies First Quarter 2025 Investor Call. [Operator Instructions] Please note, this conference is being recorded.
Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Lags Revenue Estimates
Biorestorative Therapies, Inc. (BRTX) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.53 per share a year ago.
BioRestorative Therapies, Inc. (BRTX) Q4 2024 Earnings Call Transcript
BioRestorative Therapies, Inc. (NASDAQ:BRTX ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Stephen Kilmer – Investor Relations Lance Alstodt – Chairman and Chief Executive Officer Rob Kristal – Chief Financial Officer Francisco Silva – Vice President-Research and Development Conference Call Participants Michael Okunewitch – Maxim Group Elemer Piros – Rodman & Renshaw Operator Good afternoon, everyone, and welcome to the BioRestorative Therapies 2024 Results Conference Call. At this time all participants are in a listen-only mode [Operator Instructions] Please note this conference is being recorded.
BioRestorative Therapies, Inc. (BRTX) Q3 2024 Earnings Call Transcript
BioRestorative Therapies, Inc. (NASDAQ:BRTX ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Stephen Kilmer – Investor Relations Lance Alstodt – Chairman and Chief Executive Officer Francisco Silva – Vice President-Research and Development Conference Call Participants Jonathan Aschoff – ROTH Capital Michael Okunewitch – Maxim Group Elemer Piros – Rodman Operator Greetings. Welcome to the BioRestorative Third Quarter 2024 Results and New Additional Preliminary BRTX-100 Phase 2 Study Data Review Conference Call.
